Design Therapeutics Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Design Therapeutics Inc
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company’s product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
/ 
Frequently asked questions
To buy Design Therapeutics Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Design Therapeutics Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Design Therapeutics Inc is DSGN:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Design Therapeutics Inc has its primary listing on NASDAQ. You can trade Design Therapeutics Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Design Therapeutics Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Design Therapeutics Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Design Therapeutics Inc.